In the last few decades, the treatment efficacy of breast cancer has improved tremendously, and various prognostic biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have been identified [2, 3]. This evidence concerns the gene ESR1 and breast carcinoma.